Comparative Pharmacology
Head-to-head clinical analysis: CICLOPIROX versus MYHIBBIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CICLOPIROX versus MYHIBBIN.
CICLOPIROX vs MYHIBBIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Ciclopirox is a hydroxypyridone antifungal agent that chelates polyvalent metal cations (e.g., Fe3+, Al3+) inhibiting metal-dependent enzymes, thereby disrupting fungal cellular metabolic processes, including mitochondrial electron transport and energy production.
Myhibbin is a selective inhibitor of inosine monophosphate dehydrogenase (IMPDH), thereby blocking the de novo synthesis of guanosine nucleotides. This inhibits T- and B-lymphocyte proliferation and antibody production.
Ciclopirox 8% nail lacquer: Apply to affected nails once daily for up to 48 weeks. Ciclopirox 1% cream or lotion: Apply to affected skin twice daily for 2-4 weeks. Ciclopirox 1% shampoo: Apply to wet hair, lather, leave for 3 minutes, rinse; use twice weekly for 4 weeks (for seborrheic dermatitis).
MYHIBBIN is not a recognized FDA-approved drug. No standard dosing information is available.
None Documented
None Documented
Clinical Note
moderateCiclopirox + Tranilast
"The risk or severity of adverse effects can be increased when Ciclopirox is combined with Tranilast."
Clinical Note
moderateCiclopirox + Tolfenamic acid
"The risk or severity of adverse effects can be increased when Ciclopirox is combined with Tolfenamic acid."
Clinical Note
moderateCiclopirox + Nimesulide
"The risk or severity of adverse effects can be increased when Ciclopirox is combined with Nimesulide."
Clinical Note
moderateCiclopirox + Risedronic acid
Terminal elimination half-life: 1.7-3.0 hours in healthy individuals; prolonged in hepatic impairment
Terminal half-life: 12-15 hours in adults; prolonged in renal impairment (up to 30 hours)
Renal: approximately 70-80% of the absorbed dose as unchanged drug and glucuronide conjugates; biliary/fecal: ~20-30%
Renal excretion as unchanged drug (70-80%), biliary/fecal (15-20%)
Category A/B
Category C
Antifungal
Antifungal
"The risk or severity of adverse effects can be increased when Ciclopirox is combined with Risedronic acid."